title: Treatment of malignant superior vena cava syndrome by endovascular stent insertion. Experience on 52 patients with lung cancer.
abstract: BACKGROUND
  Superior vena cava syndrome (SVCS) is a frequent presentation of malignancies involving the mediastinum and can seriously compromise treatment options and prognosis. Stenting of superior vena cava is a well-known but not so commonly used technique to alleviate this syndrome.
  
  
  METHODS
  Between August 1993 and December 2000 we performed 52 stenting procedures in patients affected by non-small cell lung cancer (NSCLC).
  
  
  RESULTS
  Phlebographic resolution of the obstruction was achieved in 100% of cases with symptomatic and subjective improvement in more than 80%. One major complication was observed due to bleeding during anticoagulation. Re-obstruction of the stent occurred in only 17% of the cases, the majority due to disease progression. Improvement of the syndrome allowed hydration necessary for full dose platinum treatment when indicated in patients affected by lung cancer.
  
  
  CONCLUSIONS
  Stenting of the superior vena cava syndrome is a safe and effective procedure achieving a rapid alleviation of symptoms in almost all patients, and allowing for full dose treatment in lung cancer patients. This procedure could change the traditional poorer prognosis attributed to non-small cell lung cancer patients presenting with this syndrome.
authors.affiliation: Medical Oncology Department, Institut Català d'Oncologia, Hospital Universitari de Bellvitge, L'Hospitalet, Barcelona, Spain.
authors.forename: A
authors.initials: A
authors.lastname: Urruticoechea
authors.forename: R
authors.initials: R
authors.lastname: Mesía
authors.forename: J
authors.initials: J
authors.lastname: Domínguez
authors.forename: C
authors.initials: C
authors.lastname: Falo
authors.forename: E
authors.initials: E
authors.lastname: Escalante
authors.forename: A
authors.initials: A
authors.lastname: Montes
authors.forename: C
authors.initials: C
authors.lastname: Sancho
authors.forename: F
authors.initials: F
authors.lastname: Cardenal
authors.forename: M
authors.initials: M
authors.lastname: Majem
authors.forename: J R
authors.initials: JR
authors.lastname: Germà
mesh_terms: D000328:Adult; D000368:Aged; D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use; D018450:Disease Progression; D005260:Female; D006470:Hemorrhage / Q000209:etiology; D006801:Humans; D008175:Lung Neoplasms / Q000150:complications*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D015607:Stents; D013479:Superior Vena Cava Syndrome / Q000209:etiology* / Q000473:pathology / Q000601:surgery*; D016896:Treatment Outcome; D014656:Vascular Surgical Procedures / Q000295:instrumentation / Q000379:methods*
chemical_list: D000925:Anticoagulants